InflaRx N.V. a présenté plusieurs analyses de données de l'étude de phase 3 du vilobelimab dans le pyoderma gangrenosum , ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback